surmount-1 trial tirzepatide weight loss non-diabetic SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, surmount-1 trial tirzepatide non-diabetic obesity

Avoiding obesity care violates first, do no harm

At a glance 150mg and 300mg tablets

PlexusDx offers both oral and injectable tirzepatide formulations through licensed 503A compounding pharmacies, allowing patients to choose the delivery method that best suits their needs

When used appropriately by qualified candidates, GLP-1s can lead to significant weight loss

Among patients who stopped taking tirzepatide, 31.0% doubled their weight loss after two years, 15.2% lost some additional weight, and 9.0% maintained their initial loss, with 55.2% in total maintaining or losing more weight

Regular physical exercise Incorporating regular exercise into your routine will enhance the effects of Semaglutide GLP-1